4th Oct 2019 08:39
(Alliance News) - Biopharmaceutical firm Hutchison China Meditech Ltd on Friday said it has dosed the first patient in its international early-stage study of HMPL-523 in lymphoma.
The phase 1/1b study has begun, with the first patient dosed on Thursday last week, and its "primary outcome measures are safety and tolerability". The study will also assess efficacy measures like objective response rate as a secondary outcome.
The trial will assess patients with relapsed or refractory lymphoma, meaning their cancer has either not responded to treatment or has stopped responding. Lymphoma is a type of blood cancer that develops in cells called lymphocytes and spreads through the body's lymphatic system.
The study will take place globally and has sites in both Europe and the US. It "complements" Hutchison China's "ongoing phase 1b dose expansion program of HMPL-523 in Australia and China addressing a broad range of hematological cancers".
Shares in Hutchison China were untraded at 295.00 pence in London on Friday morning.
By Anna Farley; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed